It confirms my suspicion that Lemtrada will be a dark horse to take away sales from many of the leaders(Rebif, Avonex, Copaxone). Did they talk about pricing or hint at priority review?
Really impressive data and truly helps MS patients get away from being defined by the disease(constant injections etc). Good to see that the deaths dont appear related to Lemtrada. Altough anecdotal, there does seem to be a good amount of enthusiasm for the drug via patients/doctors.
Market Data 
Markets 
AI
